Ga offline met de app Player FM !
Podcasts die het beluisteren waard zijn
GESPONSORDE
![<div class="span index">1</div> <span><a class="" data-remote="true" data-type="html" href="/series/travis-makes-money">Travis Makes Money</a></span> podcast artwork](https://cdn.player.fm/images/32243849/series/wgCXadnk2StIFlzM/32.jpg 32w, https://cdn.player.fm/images/32243849/series/wgCXadnk2StIFlzM/64.jpg 64w, https://cdn.player.fm/images/32243849/series/wgCXadnk2StIFlzM/128.jpg 128w, https://cdn.player.fm/images/32243849/series/wgCXadnk2StIFlzM/256.jpg 256w, https://cdn.player.fm/images/32243849/series/wgCXadnk2StIFlzM/512.jpg 512w)
![<div class="span index">1</div> <span><a class="" data-remote="true" data-type="html" href="/series/travis-makes-money">Travis Makes Money</a></span> podcast artwork](/static/images/64pixel.png)
02_06 HER-2 Low Breast Cancer and Sacutuzumab Govetecan
Manage episode 352932939 series 3335024
1. HER-2 Testing Algorithm
2. Trastuzumab Deruxtecan in HER-2 Low MBC
3. 2:1 Randomization, Treatment of Provider Choice
4. Sacutuzumab Govetacan for later line TNBC and HR positive MBC
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
Some highlighted references recommended to read related to this specific episode:
1.Wolff A et al. JCO. 2018;36(20):2105-2122. doi:10.1200/JCO.2018.77.8738
2.Modi S et al. NEJM. 2022;387(1):9-20. doi:10.1056/NEJMOA2203690/
3.BardiaI A et al. NEJM. 2021;384:1529-1541. doi:10.1056/NEJMOA2028485
4.Rugo H et al. JCO. Published online Aug 26, 2022 . doi:10.1200/JCO.22.01002
5.Rugo H et al. Ann Oncol. 2022;33(suppl_7):S808-S869. doi:10.1016/annonc/annonc1089
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
Thanks to Feed Spot for recognition as one of the best oncology podcasts!
https://blog.feedspot.com/oncology_podcasts/
49 afleveringen
02_06 HER-2 Low Breast Cancer and Sacutuzumab Govetecan
Talking About Tumors with Ryann and Ryan - A medical oncology podcast
Manage episode 352932939 series 3335024
1. HER-2 Testing Algorithm
2. Trastuzumab Deruxtecan in HER-2 Low MBC
3. 2:1 Randomization, Treatment of Provider Choice
4. Sacutuzumab Govetacan for later line TNBC and HR positive MBC
Citations
As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.
DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.
Uptodate.com Waltham, MA: Wolters Kluwer.
Some highlighted references recommended to read related to this specific episode:
1.Wolff A et al. JCO. 2018;36(20):2105-2122. doi:10.1200/JCO.2018.77.8738
2.Modi S et al. NEJM. 2022;387(1):9-20. doi:10.1056/NEJMOA2203690/
3.BardiaI A et al. NEJM. 2021;384:1529-1541. doi:10.1056/NEJMOA2028485
4.Rugo H et al. JCO. Published online Aug 26, 2022 . doi:10.1200/JCO.22.01002
5.Rugo H et al. Ann Oncol. 2022;33(suppl_7):S808-S869. doi:10.1016/annonc/annonc1089
Disclosures
Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.
Tags
Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology
Thanks to Feed Spot for recognition as one of the best oncology podcasts!
https://blog.feedspot.com/oncology_podcasts/
49 afleveringen
Όλα τα επεισόδια
×Welkom op Player FM!
Player FM scant het web op podcasts van hoge kwaliteit waarvan u nu kunt genieten. Het is de beste podcast-app en werkt op Android, iPhone en internet. Aanmelden om abonnementen op verschillende apparaten te synchroniseren.